ATOS vs. AKBA, PRME, ORKA, RVNC, TKNO, ETON, AURA, ATXS, PHAT, and GLUE
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Akebia Therapeutics (AKBA), Prime Medicine (PRME), Oruka Therapeutics (ORKA), Revance Therapeutics (RVNC), Alpha Teknova (TKNO), Eton Pharmaceuticals (ETON), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Phathom Pharmaceuticals (PHAT), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.
Atossa Therapeutics vs.
Akebia Therapeutics (NASDAQ:AKBA) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Atossa Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Atossa Therapeutics' return on equity.
Akebia Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Akebia Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 313.22%. Atossa Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 835.83%. Given Atossa Therapeutics' higher possible upside, analysts plainly believe Atossa Therapeutics is more favorable than Akebia Therapeutics.
33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 4.1% of Akebia Therapeutics shares are held by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.83 beat Atossa Therapeutics' score of 0.36 indicating that Akebia Therapeutics is being referred to more favorably in the media.
Akebia Therapeutics received 176 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. However, 65.22% of users gave Atossa Therapeutics an outperform vote while only 63.32% of users gave Akebia Therapeutics an outperform vote.
Summary
Atossa Therapeutics beats Akebia Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATOS) was last updated on 3/3/2025 by MarketBeat.com Staff
Free ATOS Stock Alerts